Articles Archives - Page 116 of 626

MondayNov 21, 2022 1:30 pm

Vision Energy Corp. (VIHDD) Accelerates Efforts for Development of Pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands

Vision Energy is in advanced stages of planning for construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels Vision Energy, through its wholly owned subsidiary Evolution Terminals BV, just announced partnership with Linde Engineering, a leading global industrial gases and engineering company, to deliver preliminary Front-End Engineering and Design (“FEED”) services to the project Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel…

MondayNov 21, 2022 12:45 pm

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Helps Power Global EV Adoption through Innovation

Worldwide initiatives to slash carbon emissions, recently bolstered by the Inflation Reduction Act in the United States, are underpinned by EV uptake, which needs innovation to scale and reach critical mass Hillcrest Energy Technologies has developed a cutting-edge 250-kilowatt, 800-volt Silicon Carbide (“SiC”) EV inverter that has captured the attention of leading firms Hillcrest has recently inked new partnerships, including one with a global Tier 1 automotive supplier, for the purpose of commercializing new inverters for electric mobility applications With 1.4 billion vehicles in use today and around 1 percent of them powered by electricity, the move to decarbonize the…

MondayNov 21, 2022 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions…

MondayNov 21, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020 Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it…

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

MondayNov 21, 2022 9:00 am

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is Powering a Clean Energy Future with Carbon-Negative RNG

RNG is considered carbon-neutral because it is derived from organic sources that produce methane emissions while decaying EverGen is developing Canadian RNG infrastructure with projects in British Columbia, Alberta, and Ontario EverGen’s expansion projects backed by Canada’s highly regulated energy sector, supported with long-term contracted revenue agreements According to the United Nations, the future of clean energy depends on fuel sources that are economical and reliable while minimizing carbon emissions (https://ibn.fm/NSl40). Sources with a minimal or zero carbon footprint like liquified natural gas (“LNG”), solar panels, and wind turbines are viable options, however renewable natural gas (“RNG”) provides a stronger…

FridayNov 18, 2022 11:15 am

DGE’s 2nd Advancing Diversity Equity & Inclusion In Pharma & Healthcare Summit

DE&I leaders, executives, and professionals from the pharma, biotech, healthcare, and allied industries, are invited to the 2nd Advancing Diversity Equity & Inclusion (“ADEI”) In Pharma and Healthcare Summit. This online live-streaming event will be held on December 8-9, 2022. The agenda will guide you to move from awareness towards advocacy and action, as you build a culture of representation and inclusion for success in the workplace and clinical trial management. Professionals and industry experts from the medical realm gather on this forum to discuss and explore ways to attain success and improve the patient’s overall experience. This live-streaming event…

FridayNov 18, 2022 10:30 am

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Modular Green Ammonia System Represents Needed and Timely Solution to Global Food and Energy Resilience

FuelPositive Corp. is a Canadian developer of clean energy solutions, focusing on an on-site system for producing hydrogen-dense green ammonia The company’s modular system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia — the amount needed to fertilize a 2,000-acre farm The system’s ability to grant end users greater energy independence as a climate-friendly resource is filling a market need at an opportune time as industries struggle to manage supply chain challenges created by COVID and the ongoing Russia-Ukraine war The module is being tested in a pilot project by Canadian farmers and…

FridayNov 18, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany BiondVax Pharmaceuticals (NASDAQ: BVXV),…

Site Search

Company Search

Category: Articles